Novocure Receives Japanese Approval for Optune Lua in Advanced NSCLC

Reuters10-30

Novocure Receives Japanese Approval for Optune Lua in Advanced NSCLC

Novocure Ltd. recently announced several significant regulatory milestones for its Tumor Treating Fields (TTFields) therapies. In August 2025, Optune Gio received coverage from the Spanish National Health System for adult patients with newly diagnosed glioblastoma. Additionally, in September 2025, the Japanese Ministry of Health, Labour and Welfare approved Optune Lua for use in combination with PD-1/PD-L1 inhibitors in adult patients with unresectable advanced or recurrent non-small cell lung cancer (NSCLC) who have progressed following platinum-based chemotherapy. Novocure also noted that its premarket approval application for TTFields therapy in pancreatic cancer is under substantive review by the U.S. Food and Drug Administration.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Novocure Ltd. published the original content used to generate this news brief via Business Wire (Ref. ID: 20251030825661) on October 30, 2025, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2579117660?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-10-30 19:01","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2579117660","market":"us","top_or_hot":-1,"title":"Novocure Receives Japanese Approval for Optune Lua in Advanced NSCLC","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Novocure Receives Japanese Approval for Optune Lua in Advanced NSCLC\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Novocure Ltd. recently announced several significant regulatory milestones for its Tumor Treating Fields (TTFields) therapies. In August 2025, Optune Gio received coverage from the Spanish National Health System for adult patients with newly diagnosed glioblastoma. Additionally, in September 2025, the Japanese Ministry of Health, Labour and Welfare approved Optune Lua for use in combination with PD-1/PD-L1 inhibitors in adult patients with unresectable advanced or recurrent non-small cell lung cancer (NSCLC) who have progressed following platinum-based chemotherapy. Novocure also noted that its premarket approval application for TTFields therapy in pancreatic cancer is under substantive review by the U.S. Food and Drug Administration.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Novocure Ltd. published the original content used to generate this news brief via Business Wire (Ref. ID: 20251030825661) on October 30, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Novocure Receives Japanese Approval for Optune Lua in Advanced NSCLC</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNovocure Receives Japanese Approval for Optune Lua in Advanced NSCLC\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-10-30 19:01</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Novocure Receives Japanese Approval for Optune Lua in Advanced NSCLC\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Novocure Ltd. recently announced several significant regulatory milestones for its Tumor Treating Fields (TTFields) therapies. In August 2025, Optune Gio received coverage from the Spanish National Health System for adult patients with newly diagnosed glioblastoma. Additionally, in September 2025, the Japanese Ministry of Health, Labour and Welfare approved Optune Lua for use in combination with PD-1/PD-L1 inhibitors in adult patients with unresectable advanced or recurrent non-small cell lung cancer (NSCLC) who have progressed following platinum-based chemotherapy. Novocure also noted that its premarket approval application for TTFields therapy in pancreatic cancer is under substantive review by the U.S. Food and Drug Administration.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Novocure Ltd. published the original content used to generate this news brief via Business Wire (Ref. ID: 20251030825661) on October 30, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4082","symbol_name":"医疗保健设备","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251030:nNDL2WxtR9:1","article_id":"2579117660","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2579117660","pubTimestamp":1761822104,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Novocure Ltd. recently announced several significant regulatory milestones for its Tumor Treating Fields  therapies. In August 2025, Optune Gio received coverage from the Spanish National Health System for adult patients with newly diagnosed glioblastoma. Additionally, in September 2025, the Japanese Ministry of Health, Labour and Welfare approved Optune Lua for use in combination with PD-1/PD-L1 inhibitors in adult patients with unresectable advanced or recurrent non-small cell lung cancer  who have progressed following platinum-based chemotherapy. Novocure also noted that its premarket approval application for TTFields therapy in pancreatic cancer is under substantive review by the U.S. Food and Drug Administration.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial,","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4082":"医疗保健设备","BK4534":"瑞士信贷持仓","BK4548":"巴美列捷福持仓","BK4588":"碎股","BK4585":"ETF&股票定投概念","NVCR":"NovoCure Limited"},"translate_title":"Novocure获得日本批准Optune Lua治疗晚期非小细胞肺癌","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"NVCR":0.9},"content_text":"Novocure Receives Japanese Approval for Optune Lua in Advanced NSCLC\n    \n\n        Novocure Ltd. recently announced several significant regulatory milestones for its Tumor Treating Fields (TTFields) therapies. In August 2025, Optune Gio received coverage from the Spanish National Health System for adult patients with newly diagnosed glioblastoma. Additionally, in September 2025, the Japanese Ministry of Health, Labour and Welfare approved Optune Lua for use in combination with PD-1/PD-L1 inhibitors in adult patients with unresectable advanced or recurrent non-small cell lung cancer (NSCLC) who have progressed following platinum-based chemotherapy. Novocure also noted that its premarket approval application for TTFields therapy in pancreatic cancer is under substantive review by the U.S. Food and Drug Administration.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Novocure Ltd. published the original content used to generate this news brief via Business Wire (Ref. ID: 20251030825661) on October 30, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.9","shortVersion":"4.35.9","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2579117660","isCrawlerRequest":true}